Can-Fite BioPharma (CANF) Stock Price, News & Analysis

Company Overview

Can-Fite BioPharma Ltd. (NYSE: CANF) is an Israel-based biopharmaceutical company focused on the development of small-molecule therapeutic candidates that target inflammation, cancer, and liver disease. Founded in 1996 and headquartered in Petach Tikva, Can-Fite leverages its proprietary technology platform to discover and advance novel adenosine receptor modulators, which act on the body’s immune and inflammatory pathways.

The company’s lead clinical programs include Piclidenoson (CF101), an oral A3 adenosine receptor agonist in late-stage development for the treatment of moderate to severe plaque psoriasis, and Namodenoson (CF102), aimed at patients with advanced hepatocellular carcinoma and nonalcoholic steatohepatitis (NASH). Can-Fite has reported positive safety and efficacy data in multiple phase II and III studies, underscoring the potential of its pipeline to address significant unmet medical needs.

Can-Fite maintains research and development facilities in Israel and operates a U.S. administrative office in North Carolina to support clinical collaborations and investigator-initiated trials. The company has forged strategic partnerships with academic institutions, contract research organizations, and specialty pharmaceutical firms to accelerate development and broaden geographic reach, including markets in North America, Europe, and Asia.

Under the leadership of President and CEO Pnina Fishman, Can-Fite’s management team combines deep expertise in clinical development, regulatory affairs, and commercial strategy. Driven by a commitment to innovation and patient-centered outcomes, Can-Fite continues to build a diversified pipeline of oral small molecules designed to deliver new therapeutic options for global patient populations.

Key Stats

• Today's Range: $1.02 to $1.05
• 50-Day Range: $1.02 to $1.15
• 52-Week Range: $0.98 to $4.69
• Volume: 31,778 shs
• Average Volume: 239,840 shs
• Market Capitalization: $3.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Buy

Can-Fite BioPharma Stock Analysis - MarketRank™

Can-Fite BioPharma scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Can-Fite BioPharma has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Can-Fite BioPharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Can-Fite BioPharma are expected to grow in the coming year, from ($1.25) to ($0.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Can-Fite BioPharma is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Can-Fite BioPharma is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Can-Fite BioPharma has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.74% of the float of Can-Fite BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Can-Fite BioPharma has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Can-Fite BioPharma has recently increased by 353.42%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Can-Fite BioPharma does not currently pay a dividend.

Dividend Growth

Can-Fite BioPharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.74% of the float of Can-Fite BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Can-Fite BioPharma has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Can-Fite BioPharma has recently increased by 353.42%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.80% of the stock of Can-Fite BioPharma is held by insiders.

Percentage Held by Institutions

Only 21.00% of the stock of Can-Fite BioPharma is held by institutions.

CANF Stock Analysis - Frequently Asked Questions

How have CANF shares performed this year?

Can-Fite BioPharma's stock was trading at $1.6250 at the start of the year. Since then, CANF stock has decreased by 36.3% and is now trading at $1.0350.

How were Can-Fite BioPharma's earnings last quarter?

Can-Fite BioPharma Ltd. (NYSE:CANF) issued its earnings results on Tuesday, November, 30th. The company reported ($1.90) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by $1.00. The company had revenue of $0.25 million for the quarter.

When did Can-Fite BioPharma's stock split?

Shares of Can-Fite BioPharma reverse split before market open on Monday, January 9th 2023.The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Can-Fite BioPharma?

Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Can-Fite BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Can-Fite BioPharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Meta Platforms (META), Broadcom (AVGO), Novo Nordisk A/S (NVO) and Adobe (ADBE).

Company Calendar

• Last Earnings: 11/30/2021
• Today: 7/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:CANF
• CIK: 1536196
• Web: www.canfite.com
• Phone: 972-3-924-1114
• Fax: 972-3924-9378
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Can-Fite BioPharma: $14.00
• High Price Target: $18.00
• Low Price Target: $10.00
• Potential Upside/Downside: +1,252.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.93
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $674 thousand
• Price / Sales: 5.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.76 per share
• Price / Book: 0.59

Miscellaneous

• Outstanding Shares: 3,540,000
• Free Float: N/A
• Market Cap: $3.66 million
• Optionable: Not Optionable
• Beta: 1.11